CircATF6 acts as a scaffold to form a circATF6/CALR/CAPN2 ternary complex, facilitating degradation of CALR (Calreticulin) by CAPN2 (Calpain 2), thereby inhibiting HCC progression (43). The gene discussed is CAPN2; the disease is hepatocellular carcinoma.